AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01649089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Lymphadenectomy
Description: Undergo lymphadenectomy
Study NCT03120195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The EndoRotor®
Description: The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.
Study NCT02129088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
Study NCT02129088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
Study NCT01950013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training program
Description: Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
Study NCT01950013 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Active Control
Description: This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
Study NCT01659476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine(MCh) Challenge Testing
Description: Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine.
Study NCT01659476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine(MCh) Challenge Testing
Description: Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.~Visit 2: Subjects will perform the opposite protocol, based on their first visit:
Study NCT02299791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALL
Description: This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.~1. EHR tools to expedite identification~   a. EHR automated point-of-care alerts (Best Practice Alerts)~2. EHR tools to expedite prescribing~   1. EHR order sets~  2. EHR text shortcuts for notation~  3. patient education materials (handout, poster)~3. EHR-based outreach support tools a. EHR registries
Study NCT02299791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALL
Description: These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
Study NCT01110148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-based informed consent for skin biopsies
Description: video-based informed consent for punch and shave biopsies
Study NCT01110148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional informed consent
Description: traditional informed consent (standard of care) from physicians for shave and punch biopsies
Study NCT05231096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloe-vera gel
Description: Aloe-Vera gel Production Aloe vera gel used in this study was 98% aloe vera gel concentration and 2% normal saline. Preparation of aloe-vera gel consists of ripen leaf of aloe vera.(26) Aloe vera leaf was washed thoroughly under water and then cut from the center and the seeping gel was collected in sterile container and was stored at 4°C until the time of application. In our research this pure Aloe vera gel was extracted by The Pakistan Council of Scientific \& Industrial Research (PCSIR) laboratory.
Study NCT05231096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sidr honey
Description: Honey collection Sidr (Beri) honey was used in this study. Honey was thick, raw and cold extracted from remote Pakistan afghan tribal forest belt of Sidr trees. It was smooth, viscous and medium to dark amber in color.
Study NCT05231096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling ans root Debridement
Description: non-surgical periodontal therapy was given to all the participants of all the three groups
Study NCT05231096 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scaling ans root Debridement
Description: non-surgical periodontal therapy was given to all the participants of all the three groups
Study NCT02943304 — intervention group
Intervention type: OTHER
Intervention: Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
Study NCT00637780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
Study NCT06035419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: breastfeeding education for migrant mothers
Study NCT02086513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: Treatment with LDE225
Study NCT04971317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage (SSB) Video
Description: Participants will watch a video showing the decay of an egg in various SSBs (Coca-Cola, Sprite, Gatorade, and apple juice), followed by the evaporation of these beverages over a heat source, revealing their sugar content.
Study NCT04971317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water Video
Description: Participants will watch a video showing an egg maintaining its shell in water, followed by the evaporation of water.
Study NCT04971317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will watch a video of an egg maintaining its shell in rubbing alcohol, followed by the evaporation of rubbing alcohol.
Study NCT01284036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-05230905
Description: Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
Study NCT00687141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
Study NCT00687141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
Study NCT00832624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
Study NCT03899181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Translumbosacral Neuromodulation Therapy (TNT)
Description: A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.
Study NCT03899181 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TNT Therapy
Description: This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.
Study NCT02739685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffold
Description: Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
Study NCT02739685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Implantation of everolimus-eluting stent in chronic total occlusion
Study NCT03584880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser disinfection
Description: Root canal disinfection using a 940 nm dental laser after the removal of root canal filling of failed endodontic cases.
Study NCT03584880 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pseudo diode laser disinfection
Description: Without activating laser energy, same procedure as experimental group was performed (Sham laser application)
Study NCT04519242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.~PA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).~Type and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon.
Study NCT00653939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosbretabulin
Description: Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
Study NCT00653939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
Study NCT00653939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
Study NCT00653939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
Study NCT00653939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
Study NCT01775631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT00993811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shang Ring circumcision
Description: novel device for adult male circumcision
Study NCT03136315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INFERNAL Intervention
Description: The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
Study NCT03315767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ARFI-elastography and portal vein flow measurement
Description: Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.
Study NCT03315767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HVPG-measurement
Description: Evaluation of Portal Hypertension by HVPG-measurement
Study NCT00653939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
Study NCT00653939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
Study NCT01519193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for violent offenders (NETvo)
Description: During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
Study NCT01443624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: critical care patients venofer
Description: 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
Study NCT04185116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Optic System (Olympus VISERA Elite II 3D)
Description: Use of the 3D Optic System Olympus VISERA Elite II 3D
Study NCT02194374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROR1R-CAR-T Cell Infusion
Description: Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort.
Study NCT02194374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.~FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3.
Study NCT02194374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
Study NCT02194374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.~BR Regimen: 375-500 mg/m2 by vein on Day -4.
Study NCT02194374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.~FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3.
Study NCT01238484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: shoe modification home stretching exercises
Study NCT01238484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint
Description: shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
Study NCT00870376 — intervention group
Intervention type: OTHER
Intervention: biomarkers
Description: To define a biomarker or combination of overactive bladder syndrome
Study NCT01380626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise training
Description: strength and endurance training, 5 time per week.
Study NCT01040117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory-motor Integration Training
Description: Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.
Study NCT01040117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional neurorehabilitation treatment
Description: The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.~Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position.
Study NCT05926518 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling
Description: Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.
Study NCT02878798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: Oral topiramate at a target dose of 50mg twice daily.
Study NCT02878798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: overencapsulated placebo of identical color, shape and packaging to topiramate
Study NCT02377661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil, amlodipine, hydrochlorothiazide
Description: Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of \< 140/90 mmHg is not reached at the respective follow-up
Study NCT04713397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Leg Length Discrepancy Scoliometer Test
Description: A scoliometer used as an indirect and quantitative method to evaluate LLD for the first time in this study, and described it as Leg Length Discrepancy Scoliometer Test. Scoliometer were used on Adams' forward bending position and the level of the pelvis accepted as equal when the scoliometer degree pointed zero on the sacral basis (angle of trunk rotation on sacrum). When considering pelvis level is high on the longer side and is low on the shorter side, if the angle of the scoliometer on the sacrum is negative (slope to the left), the left extremity was considered as shorter. In order to determine its correlation with an indirect method, scoliometer degree on the sacral basis was recorded then wooden blocks were added to the unequal leg side on the sacral basis until the pelvic equality was achieved on the scoliometer. Afterward, a correlation between the first measurement of ATRsacrum and the height of the wooden block which provides ATRsacrum to reach zero was investigated.
Study NCT03891238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
Study NCT00932061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Acupuncture
Description: Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria.
Study NCT00932061 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria.
Study NCT03811860 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lithium level
Description: The level of lithium in the serum
Study NCT03811860 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Creatinine
Description: The level of creatinine (as an indicator of kidney function, to approximate GFR) in the serum
Study NCT03706248 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: 20 ml of blood will be drawn from subjects via venipuncture
Study NCT01715441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and irinotecan combination
Study NCT01715441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib monotherapy
Study NCT01715441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan monotherapy
Study NCT03309176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone Acetate 10 MG
Description: Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
Study NCT03309176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stair step protocol without Medroxyprogesterone Acetate
Description: No administration of Medroxyprogesterone Acetate prior to each cycle. Stair step method: rapidly increasing the dose of clomiphene citrate in case of no follicular response